Emerging Company Showcase 2023

Transformative Innovations, Visionary Founders 

Each company featured in the 2023 Emerging Company Showcase was nominated, reviewed and invited to present based upon their transformative innovations and the enterprising team. They presented before a panel of ‘Pitch Doctors’, early stage VCs and investors, corporate VCs, strategic partners and other investors and advisors, who provide critical feedback and actionable guidance.

2023 Presenting Companies

	7 Hills Pharma, LLC, Research Triangle Park, NC: Developing first-in-concept integrin activators to augment immunotherapies for the treatment of drug resistant solid tumors and infectious diseases.
	Arpeggio Biosciences, Boulder, CO: Developing high-throughput transcriptomics platform to predict efficacy more accurately and identify new therapies for drug-resistant cancer.
	Cayuga Biotech, New York, NY: Developing a biomimetic drug addressing life-threatening hemorrhage in white space indications; and programs as well as rare inherited bleeding disorders, platelet dysfunction, traumatic brain injury, severe burn and wound healing.
	CytoDel, Inc., New York, NY: Developing recombinant botulinum toxin (rBoT) derivatives that can deliver therapeutics to the neuronal cytoplasm
	DAYI Therapeutics, New York, NY: Novel AI driven target discovery and ASO screening platform for monogenic diseases
	Dignify Therapeutics, LLC, Durham, NC: Developing treatments (drugs and devices) for voiding dysfunction (bladder and bowel) associated with spinal cord injury, diabetes, aging, etc.
	EicOsis, LLC, Davis, CA: Developing a new class of non-opioid, oral treatment for inflammatory and neuropathic pain.
	Epiodyne, Inc., San Francisco, CA: Developing small-molecule opioid medicines with specifically calibrated functions that address pain management and Opioid Use Disorder (OUD).
	Helex, New York, NY: Utilizing epigenetics and 3D genome structures through data and machine learning to design high precision gene editing systems and evaluate edit impact on global genome for safer therapeutics.
	Kannalife, Inc., Doylestown, PA: Developing cannabinoid-inspired therapeutics as potent, non-opioid alternatives to treat patients with significant unmet medical needs
	Kuda Therapeutics, Inc., Salt Lake City, UT: Developing a small molecule with a dual mechanism of action of blocking the tumor driver, hypoxia-inducible factor (HIF)-2α and inducing cell death through excessive iron accumulation for the treatment of kidney cancer.
	Lime Therapeutics – A Memorial Sloan Kettering Cancer Center spinout using its breakthrough phenotypic screening platform to create lipid-targeting therapeutics for non-small cell lung, pancreatic, and colorectal cancer.
	Microvascular Therapeutics, Tucson, AZ: Developing next generation contrast agents for diagnostic ultrasound.
	Mitomed Pharma Inc., Rockville, MD: Developing a series of unique dual-targeting highly-selective compounds that disrupt the mitochondria in cancer cells and induce cell death.
	Neurodon, LLC, Crown Point, IN: Developing therapeutics targeting SERCA for the treatment of diabetes, Alzheimer’s, Parkinson’s, Duchenne muscular dystrophy, and other rare diseases.
	Novomedix, LLC, San Diego, CA: Developing novel small molecule multi-pathway modulators for solid tumors, fibrosis, and inflammatory diseases.
	Omnitia Therapeutics, New York, NY: Developing first in class small molecules targeting cytotoxic species implicated in neurodegenerative disorders including AD and ALS/FTD.
	OncoPrecision, New York, NY: Developing Patient Micro Avatar technology which seeks to recreate cancer patients’ disease ex-vivo to precisely evaluate the response of these avatars to a wide range of both Standard of Care and explorational treatments within a week.
	Pannex Therapeutics, New York, NY: develop novel therapies to transform cancer therapy based on blocking Pannexin1 channels (Panx1).
	Phoenix Nest, Inc., Brooklyn, NY: Developing treatments for Sanfilippo Syndrome IIIC and IIID, using approaches that include enzyme replacement and chaperone therapies.
	POP Biotechnology, Buffalo, NY: Developing porphyrin-phospholipid (PoP) liposome technologies to create nanomedicines to address needs in oncology and infectious disease.
	ProJenX: New York, NY: Developing novel, brain-penetrant, targeted therapies to address neurodegenerative diseases, with an initial focus on ALS.
	RenBio, Long Island City, NY: Developing DNA based antibody and protein delivery platform to treat blood disorder, viral infection and inflammatory diseases.
	RNA Nanotherapeutics, LLC, Cincinnati, OH: Develop cancer-targeting multifunctional RNA nanoparticles targeting MED1 to treat therapeutic-resistant breast cancer.
	Sagittarius Bio, Inc., Thousand Oaks, CA: Developing an AI-enabled platform for curative responses against cancers with shared and patient-specific tumor targets
	Stingray Therapeutics, Inc., Houston, TX: Developing innate immunity modulators in the STING (STimulator of INterferon Genes) pathway including potent and selective small molecule inhibitors of ENPP1 (Ectonucleotide Pyrophosphatase / Phosphodiesterase1) as next generation cancer immunotherapies.
	Synthis Therapeutics, Inc., New York, NY: Developing a first in class therapeutic platform that rescues immune function and drives tumor clearance in advanced cancer patients.
	Tezcat Biosciences, New York, NY: Developing a portfolio of protein-drug conjugates to provide therapeutic options for patients harboring mutant RAS cancers.
	UNandUP, LLC, St. Louis, MO: Developing advanced magnetic control technologies including nanomagnetic substrates for ischemic stroke, neuroprotection, chemotherapy, immunotherapy and tumor embolization, and next-generation interventional robotic systems to improve patient outcomes in procedures in the brain, heart and lungs.
	Vincere Biosciences Inc, Cambridge, MA: Developing small molecule therapeutics for diseases of aging, including neurodegenerative diseases such as Parkinson’s disease.
	Vivreon Biosciences, LLC: San Diego, CA: Developing a new class of small molecule therapeutics for the treatment of chronic inflammatory diseases.
	View the 2022 showcase presenters here.